

# TRE-11CGG-GFP (Erasmus MC)

<https://neurodegenerationresearch.eu/survey/tre-11cgg-gfp-erasmus-mc/>

## **Name of Resource**

TRE-11CGG-GFP (Erasmus MC)

## **Name of Principal Investigator - Title**

Prof

## **Name of Principal Investigator - First name**

Rob

## **Name of Principal Investigator - Last name**

Willemsen

## **Address of institution -Institution**

Department of Clinical Genetics, Erasmus MC

## **Address of institution - Street address**

Wijtemaweg 80

## **Address of institution - City**

Rotterdam

## **Address of institution - Postcode**

3015 CN

## **Country**

The Netherlands

## **Website**

[http://www.erasmusmc.nl/klinische\\_genetica/research](http://www.erasmusmc.nl/klinische_genetica/research)

## **Contact email**

[r.willemsen@erasmusmc.nl](mailto:r.willemsen@erasmusmc.nl)

## **Summary**

Doxycycline inducible mouse model expressing a Fmr1 control size of 11CGGs coupled to

EGFP under control of a Tet-On promoter to study FXTAS; see Hukema et al. Cell Cycle 2014 and Hukema et al. Hum Mol Genet 2015

**Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions? (1)**

Neurodegenerative disease in general

**Q1b. Does your resource hold**

Animals| Frozen sperm| Genetic Material (e.g DNA, RAN, vectors)

**Q2a. Does the resource act as a centre for access and distribution to external groups (who are not the Principal Investigators (PI) for the resource)?**

Yes

**Q2b. If Yes, what procedures and rules apply for access?**

Apply to PI or co-ordinator at resource| International access| Other requirements exist

**Q3a. Does your resource develop experimental models (animal/cell) for external groups?**

No

**Q3b. If YES and your resource is related to an ANIMAL model, what types of models are provided?**

**Q3c. If YES and your resource is related to a CELL model, what types of models are provided?**

**Q4a. Is this activity supported as:**

**Q4b. Do you deposit what you supply in any kind of central repository?**  
Disease

Fragile X-associated Tremor/Ataxia Syndrome (FXTAS)

**Species**

Mouse| Mouse| Rat

**Available to external user**

yes, via TTO

**Full phenotypic character**

Partial

**Please indicate the phenotypes**

none

**List of genotypes or other subtypes**

Q5b. Cognitive function, No of models  
Q5b. Cognitive function, Available to external users  
Q5b. Cognitive function, Full phenotypic characterisation  
Q5b. Cognitive function, Nature of phenotype  
Q5b. Motor function, No of models  
Q5b. Motor function, Available to external users  
Q5b. Motor function, Full phenotypic characterisation  
Q5b. Motor function, Nature of phenotype  
Q5b. Physiological function, no of models  
Q5b. Physiological function, Available to external users  
Q5b. Physiological function, Full phenotypic characterisation  
Q5b. Physiological function, Nature of phenotype  
Q5b. Other function (please specify), no of models  
Please specify other function  
Q5b. Other function (please specify), Available to external users  
Q5b. Other function (please specify), Full phenotypic characterisation  
Q5b. Other function (please specify), Nature of phenotype  
Q6. Please indicate if your resource is already linked into European or international consortia or networks?  
Q7a. Is maintenance of this resource dependent on continued funding?  
Q7b. If yes, when does the current funding period end?

2019

Q7c. What is the expected lifespan of the resource (in years)?

2

Q7d. Are there other plans affecting future use that it may be useful to know?

**Types:**

Experimental Models

**Member States:**

Netherlands

**Diseases:**

N/A

**Years:**

2016

**Database Categories:**

N/A

**Database Tags:**

N/A